SER
AMEXSerina Therapeutics Inc.
Price$1.99+0.09 (+4.74%)
01:30 PM02:15 PM
News · 26 weeks58-42%
2025-12-282026-06-21
Mix3290d
- Insider15(47%)
- SEC Filings12(38%)
- Other5(16%)
Latest news
25 items- INSIDERDirector Venkatesan Jay bought $1,048 worth of shares (589 units at $1.78) and converted options into 224,152 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Bailey Gregory converted options into 8,437,472 shares, increasing direct ownership by 6,663% to 8,564,382 units (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Brannan Stephen K.4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilson Karen J4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Director Marshall Richard Peter4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Wilson Karen J bought $17,750 worth of shares (10,100 units at $1.76) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form EFFECT filed by Serina Therapeutics Inc.EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERChief Executive Officer Ledger Steven A was granted 10,100 shares (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by SVP, CMC & Formulation Tenjarla Srini4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Ledger Steven A4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Curhan Gregory S4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Moreadith Randall4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Wilson Karen J bought $37,000 worth of shares (20,000 units at $1.85) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERDirector Marshall Richard Peter bought $20,102 worth of shares (12,183 units at $1.65) (SEC Form 4)4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form S-3 filed by Serina Therapeutics Inc.S-3 - Serina Therapeutics, Inc. (0001708599) (Filer)
- PRSerina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesPhase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support continued advancement of SER-252 – HUNTSVILLE, May 14, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates. "With our Phase 1b registrational study of SER-252 now underway and a strengthened balance sheet, Serina
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form 10-Q filed by Serina Therapeutics Inc.10-Q - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form SCHEDULE 13G filed by Serina Therapeutics Inc.SCHEDULE 13G - Serina Therapeutics, Inc. (0001708599) (Subject)
- SECSEC Form DEFA14A filed by Serina Therapeutics Inc.DEFA14A - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSEC Form DEF 14A filed by Serina Therapeutics Inc.DEF 14A - Serina Therapeutics, Inc. (0001708599) (Filer)
- SECSerina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
- INSIDERSEC Form 4 filed by Bailey Gregory4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- INSIDERSEC Form 4 filed by Venkatesan Jay4 - Serina Therapeutics, Inc. (0001708599) (Issuer)
- SECSEC Form PRE 14A filed by Serina Therapeutics Inc.PRE 14A - Serina Therapeutics, Inc. (0001708599) (Filer)
SER FAQ
6 questionsWhere does SER stock trade?
Serina Therapeutics Inc. (SER) is listed on AMEX.What sector and industry is SER in?
Serina Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Serina Therapeutics Inc. go public?
Serina Therapeutics Inc. (SER) completed its IPO in 2018.What are analysts saying about SER?
Serina Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $1500.00 price target on 2025-07-14. Recent price targets cluster around $1500.00.What companies are similar to SER?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SER side-by-side with any of them on Quantisnow.How can I track SER on Quantisnow?
Quantisnow aggregates Serina Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SER to receive live email and push alerts on every new disclosure.